Allena Pharmaceuticals, Inc. Just Filed Its Quarterly Report: 3. Net Loss per Shar...

3. Net Loss per Share

Basic net loss per share is calcula ted by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, restricted stock units, common stock issuable upon the conversion of outstanding debt and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same.

Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data):

 
























































































































































 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(12,692

)

 

$

(8,026

)

 

$

(38,300

)

 

$

(22,587

)

Net loss attributable to common stockholders

 

$

(12,692

)

 

$

(8,026

)

 

$

(38,300

)

 

$

(22,587

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares—basic and diluted

 

 

76,658,487

 

 

 

36,260,973

 

 

 

63,283,268

 

 

 

29,317,787

 

Net loss per share attributable to common
   stockholders—basic and diluted

 

$

(0.17

)

 

$

(0.22

)

 

$

(0.61

)

 

$

(0.77

)

 

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares):

 




















































































 

 

Nine Months Ended September 30,

 

 

 

2021

 

 

2020

 

Stock options

 

 

7,188,457

 

 

 

3,678,241

 

Restricted stock units

 

 

372,166

 

 

 

547,319

 

Warrants

 

 

10,687,912

 

 

 

9,040

 

Common stock issuable upon conversion of outstanding debt

 

 

2,439,024

 

 

 

2,439,024

 

Total

 

 

20,687,559

 

 

 

6,673,624

 

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Allena Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Statement of acquisition of beneficial ownership by individuals - Jan. 25, 2022
Allena Pharmaceuticals Provides Clinical And Corporate Update ALLN-346, - Jan. 4, 2022

Auto Refresh

Feedback